Director and 10% owner Clayton Clopton Yates filed a Form 4 with the SEC on November 3, 2026, reporting the acquisition of 200,000 shares of Genvor Inc common stock on April 15, 2026, through a conversion of outstanding payables.

Key Highlights

  • Reporting person: Yates Clayton Clopton (Dr. Clayton Yates), identified as a Director and 10% Owner of Genvor Inc (GNVR).
  • Transaction: 200,000 shares of common stock acquired (transaction code A) on April 15, 2026, at a price of $0.50 per share.
  • Conversion basis: According to the filing, the shares were issued upon conversion of $100,000 in outstanding payables owed by the company to Dr. Yates under his scientific advisor agreement.
  • Post-transaction ownership: Following the transaction, Dr. Yates beneficially owns 600,000 shares, held indirectly through ACT Holdings, LLC.
  • Indirect ownership: The filing states Dr. Yates holds voting and dispositive power over shares held in the name of ACT Holdings, LLC, and is therefore deemed beneficial owner of those shares.
  • Compensation plan: The conversion was made pursuant to the company's "restructured compensation package previously approved by the Company," which the filing states permits Dr. Yates to convert amounts due to him into common stock.

Genvor Director Dr. Clayton Yates Converts $100,000 in Payables into Common Stock

According to the Form 4 filed on November 3, 2026, Dr. Clayton Yates, a director and 10% owner of Genvor Inc, reported the acquisition of 200,000 shares of common stock on April 15, 2026. The filing identifies the issuer as Genvor Inc with ticker GNVR, though no exchange designation is stated in the filing beyond the ticker symbol. The shares were acquired at a price of $0.50 per share, with the filing indicating this represents transaction code "A" (acquired).

The filing's explanation of responses states that the shares were "issued upon Dr. Yates' conversion of $100,000 in outstanding payables owed by the Company to Dr. Yates, pursuant to his scientific advisor agreement with the Company and the Company's restructured compensation package previously approved by the Company, which permits Dr. Yates to convert amounts due to him into Company common stock." No derivative securities transactions were reported in Table II of the filing.

All 600,000 shares beneficially owned following the transaction are held indirectly through ACT Holdings, LLC. The filing notes that Dr. Yates "has voting and dispositive power with respect to shares held in the name of ACT Holdings, LLC, and is therefore deemed to be beneficial owner of shares held in its name." The filing was signed by Dr. Clayton Yates on November 3, 2026.

What Was Disclosed

A Form 4 filed November 3, 2026, disclosed that Genvor Inc director and 10% owner Dr. Clayton Yates acquired 200,000 common shares on April 15, 2026, via conversion of $100,000 in payables, bringing his indirect beneficial ownership to 600,000 shares through ACT Holdings, LLC.